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Abstract 
Ribonucleotide reductase subunit M2 (RRM2) is 
located in chromosome-2 p25-p24, converts 
ribonucleotides to deoxynucleotides which is 
required for DNA polymerization and repair. It has 
been shown that RMM2 plays a key role in DNA 
synthesis, cell growth, and drug resistance of cancer 
cells. There is accumulating evidence that alteration 
in the expression level of RRM2 can have a 
substantial impact on the biological characteristics 
of cancer cells, including tumor initiation and 
progression, suggesting its role as a prognostic 
factor and a possible therapeutic target for cancer 
therapy. Therefore, this review highlights several 
recent and clinically relevant aspects of the 
expression and function of RRM2 in human cancer. 
Identity 
Other names: R2, RR2, RR2M 
HGNC (Hugo): RRM2 
Location: 2p25.1 
Local order 
Based on MapViewer, gene flanking RRM2 
oriented on 2p25-p24 are:  
- KLF11 (Kruppel-like factor 11); 2p25,  
- CYS1 (cystin 1); 2p25.1,  
- RRM2 (ribonucleotide reductase M2); 2p25-p24,  
- C2orf48 (chromosome 2 open reading frame 48); 
2p25.1,  
- MIR4261 (microRNA 4261); chromosome 2,  
- HPCAL1 (hippocalcin-like 1); 2p25.1. 
 
Table 1. Exons and introns of RRM2 gene. 
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Figure 1. Ribonucleotide reductase subunit M2 (RRM2) is located in chr 2p25-p24. Synthesis of the encoded protein RRM2 is 
regulated in a cell-cycle dependent fashion and elevated to maximal levels during S-phase of cell cycle. RRM2 has two isoforms 




RRM2 gene has ten exons, nine introns and 
alternative promoters (Table 1). The alternative 
promoters are resulting in two isoforms with 
different N-terminal lengths (variants 1 and 2; 
Figure 1). Variants 1 and 2 contain 3452 and 3284 
bp, respectively. Variant 1 is the longest isoform 
with respect to the variant 2. 
Transcription 
Promoter of RRM2 gene has two transcription start 
sites, TATA box, three CCAAT boxes and several 
GC rich in 5' of the downstream transcription 
initiation site. Variant 2 has a shorter 5' UTR and 
uses a downstream translational start codon, 
compared to the variant 1. Regions of -204 to +1 
and -659 to -257 act as a promoter for the variant 1 
(1.65 kbp) and variant 2 (3.4 kbp), respectively. 
Several studies are currently ongoing for the role of 
the 3' UTR in the regulation of RRM2 expression. 
Moreover, three CCAAT boxes exist in the region 
between transcription initiating sites at positions -
82, -109, -139 and -436. Also, the transcription of 
1.65 kbp RRM2 mRNA initiates from +1, while 3.4 
kbp mRNA RRM2 initiates at position -187 (Zhou 
and Yen, 2001). 
Synthesis of the encoded protein (RRM2) is 
regulated in a cell-cycle dependent fashion and 
elevated to maximal levels during S-phase of cell 
cycle (Figure 1). RRM2 promoter has transcription 
factor binding sites for SP1, c-Ets, MZF1, E2F, 
Lyf-1, GATA-X, HSF2, AP-1, CdxA, IK-2, Sox-5, 
SRY, Brn-2, HNF-1, STATx, GATA-1, USF (c-
Myc), Pbx-1, Oct-1, GATA-2, CRE-Bp and Nkx-2. 
3.4 kbp RRM2 mRNA is the major form in kidney, 
placenta and lung, while 1.65 kbp RRM2 mRNA is 
the main form in small intestine, colon, testis and 
thymus. RRM2 gene expression level is high in 
small intestine, colon thymus and testis tissues. In 
addition RRM2 mRNA in heart is very higher with 
respect to other tissues. Conversely, the expression 
level of RRM2 gene is low in lung and liver tissues, 
and its level is very low level in prostate, skeletal 
muscle, brain and leukocyte tissues (Zhou and Yen, 
2001; Park and Levine, 2000). 
Pseudogene 
Related pseudogenes have been identified on 
chromosomes 1 and X (1p33→p31, 1q21→q23 and 
Xp21→p11). 






Atlas Genet Cytogenet Oncol Haematol. 2014; 19(1) 34 
 





The building blocks of DNA, deoxyribonucleotide 
triphosphates (dNTPs), is provided/generated by 
ribonucleotide reductases (RNR). In fact RNR have 
a vital role in preserving the appropriate amount of 
dNTPs (dATP, dGTP, dCTP, dTTP) pool for DNA 
replication and repair by converting ribonucleotide 
diphosphates (NDP) to deoxyribonucleotide 
diphosphates (dNDP). RNR enzymes are divided 
into three different classes: I, II and III. Human 
RNR belongs to the class I. Furthermore, RNR has 
two subunits, RRM1 and RRM2. RRM1 is the 
larger subunit of RNR with respect to the RRM2. 
RRM2 isoform 1 and 2 have 449 and 389 residues, 
respectively. In particular, isoform 1 has 60 
residues more than isoform 2 inits N-terminal 
region. RRM2 interact with RRM1 through its C-
terminus region (Nordlund and Reichard, 2006; 
Eklund et al., 2001; Thelander, 2007). 
Expression 
RRM2 protein expression is increased to maximal 
level during S-phase due to E2F, as an activator of 
DNA synthesizing enzymes, however, its exression 
is reduced during G1 by E2F4 (Eklund et al., 2001; 
Nordlund and Reichard, 2006). 
Function 
RRM2 contains a KEN-box on the N-terminus that 
is recognized during the mitosis by the Cdh1-
anaphase-promoting complex and thereby becomes 
poly-ubiquitinated or depredates by proteasome 
(Nordlund and Reichard, 2006; Eklund et al., 2001; 
Thelander, 2007). RRM2 is responsible for 
producing a stable tyrosyl radical for the active site 
of RNR that is located in RRM1. In addition, 
p53R2 is 80% similar to RRM2, which can bind to 
RRM1 and form the active structure. According to 
the vital role of RNR in cell cycle and proliferation, 
RNRs can be considered as suitable targets for 
cancer treatment.  
Several studies have been demonstrated that 
inhibition of RRM2 can inhibit cancer cell growth 
and overcomes drug resistance (Aimiuwu et al., 
2012; Zhou et al., 2013).  
In particular, Zhou and colleagues showed that 
inhibition of RRM2 by novel RNR inhibitor 
COH29 inhibited the proliferation of most cell lines 
in the human cancer panel, mostly ovarian cancer 
and leukemia. In mouse xenograft models of human 
cancer, COH29 treatment reduced tumor growth 
with respect to the control group (Zhou et al., 
2013). 
Homology 
The RRM2 gene is conserved in Rhesus monkey, 
dog, chicken, cow, mouse, rat, K. lactis, fruit fly, 
mosquito, C. elegans, M. oryzae, S. cerevisiae, S. 
pombe, E. gossypii, N. crassa, and A. thaliana. 
Percentage of identity or homology of RRM2 in 
DNA and protein levels in eukaryots with respect to 
human is shown in Table 2. 
Mutations 
Note 
More than 1215 single nucleotide variations (SNPs) 
have been reported in RRM2 gene (until 5th of 
March 2014, dbSNP), such as rs15516, rs1130609, 
rs1138727, rs1138728, rs1138729, rs4668664, etc. 










Youns and colleagues recently showed that RRM2 
is overexpressed in the pancreatic cancer cell lines. 
They performed a gene expression profiling to 
identify novel molecular targets modulating the 
growth inhibitory effects of COX-2 inhibitor NS-
398 in pancreatic cancer. They found that RRM2 
was down-regulated in BxPC-3, MiaPaCa-2 and 
ASPC-1 cell lines after treatment with NS-398. 
Moreover, they identified RRM2 as a biomarker for 
the chemo-preventive effect of NS-398 in 
pancreatic cancer cells (Youns et al., 2011). 
Previous study illustrated that over-expression of 
RRM2 was associated with resistance to 
gemcitabine in pancreatic cancer (Nakano et al., 
2007). In this study the expression level of RRM2 
was analysed by q-PCR in different subclones 
during the development of acquired resistance to 
gemcitabine. This analysis showed that the 
expression level of RRM2 enhanced during the 
development of gemcitabine resistance. Moreover, 
they also evaluated the expression levels of other 
genes, RRM1, dCK, hENT1. This results illustrated 
that expression ratio significantly correlated with 
gemcitabine sensitivity in eight pancreatic cancer 
cell lines, whereas no single gene expression level 
correlated with the sensitivity, indicating that the 
sensitivity of pancreatic cancer cells to gemcitabine 
is dependent on the ratio of four factors involved in 
gemcitabine transport and metabolism. On the one 
hand, the ratio of the four gene expression 
associated with acquired gemcitabine-resistance in 
pancreatic cancer cells (Nakano et al., 2007). 
Moreover, Duxbury et al., showed that small 
interfering RNA targeting RRM2 enhanced 
chemosensitivity to gemcitabine in pancreatic 
adenocarcinoma (Duxbury et al., 2004), suggesting 
its role as an attractive target for pancreatic cancer. 
Lung cancer 
Note 
Several studies have been shown that RRM2 is 
overexpressed in lung cancer. In particular, 
Souglakos and colleagues showed that patients with 
low level of RRM2 had a significantly higher 
response rate (60% vs 14.2%), time to progression 
(9.9 vs 2.3 months), and overall survival (15.4 vs 
3.6 months) in metastatic lung adenocarcinoma 
patients treated with gemcitabine plus docetaxel 
with respect to the patients with high level of 
RRM2 (Souglakos et al., 2008). Furthermore, 
Boukovinas et al., evaluated the effect of RRM2 
expression on outcome to gemcitabine plus 
docetaxel in advanced non-small-cell lung cancer 
(NSCLC) patients. RRM1, RRM2 and BRCA1 
mRNA levels were determined by quantitative PCR 
and correlated with response, time to progression 
and survival. This study showed that the probability 
of response decreased (RRM2: Odds Ratio, 0.94; 
p<0.0001) and the risk of progression increased 
(RRM2: HR, 1.005; p = 0.01) in patients samples 
with high expression of RRM2, compared to the 
samples with low expression (Boukovinas et al., 
2008). In another recent study the prognostic value 
of RRM2 was determined in 418 patients with 
NSCLC who received adjuvant chemotherapy 
(Wang et al., 2014).  
This analysis demonstrated that patients with low 
expression of RRM2 had a significantly higher 
responce to platinum-based chemotherapy (OR = 
1.64, 95 % CI = 1.09-2.48) and a longer time to 
progression and overall survival time, with hazard 
ratio of 0.57 (0.38-0.86) and 0.47 (0.31-0.71), 
respectively (Wang et al., 2014). 
Breast cancer 
Note 
It has been shown that RRM2 is overexpressed in 
human breast carcinoma tissue (DCIS, Jensen et al., 
1994). Recently Kretschmer and colleagues 
identified molecular markers for the ductal 
carcinoma in situ using WAP-TNP8 mouse model. 
In particular, they identified seven marker genes 
(RRM2, MUC1, SPP1, FOXM1, EXO1, NUSAP1 
and DEPDC1), which were overexpressed at a very 
early stage of premalignancy and preneoplasia of 
breast carcinomas (Kretschmer et al., 2011). 
Ovarian cancer 
Note 
Ferrandina and colleagues found a association 
between RRM2 expression level and relative risk of 
death in ovarian cancer.  
In this study they evaluated the mRNA expression 
levels of several genes involved in transportation 
and metabolism of gemcitabine, including RRM2, 
in 25 primary ovarian carcinomas using q-PCR. 
They showed that samples with high RRM2 
expression had a less overall survival, OS, (median 
OS=19 months) with respect to the samples with 
low RRM2 level (median OS=36 months; 
Ferrandina et al., 2010). 
Osteosarcoma 
Note 
Fellenberg et al., in 2007 investigated the 
prognostic value of eight genes including RRM2 in 
35 formalin-fixed osteosarcoma biopsies. They 
observed a significant relation between RRM2 
expression with overall survival of the patients. 
However, the prognostic value of this gene did not 
confirm by multivariate analysis and further studies 
are needed to evaluate the prognostic role of RRM2 
in osteosarcoma (Fellenberg et al., 2007). 
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Bladder cancer 
Note 
Lu and colleagues investigated whether global gene 
expression profiling can help in predecting the 
suitability of rodent models of bladder cancer for 
the detection of cancer-related genes and prediction 
of cancer prevention in human bladder cancer and 
carcinogen-induced rodent models.  
They found that 13~34% of whole genome were 
differentially expressed between tumor and normal 
tissues in humans, Fischer-344 rats, and B6D2F1 
mice.  
Approximately 20% of these differentially 
expressed genes overlapped among species, 
corresponding to 2.6 to 4.8% of whole genes in the 
genome.  
A number of genes were consistently dysregulated 
in bladder tumors in both humans and rodents. 
Among these genes, RRM2 was up-regulated in 
tumor tissue across three species, suggesting its role 
as a potential factor in contributing to bladder 
carcinogenesis (Lu et al., 2010). 
Hepatocellular carcinoma 
Disease 
Patients with hepatocellular carcinoma (HCC) 
suffer from chronic hepatitis or liver cirrhosis. 
Satow and colleagues performed whole-genome 
RNA interference-based functional screening in 
order to identify genes that sensitize lung cancer 
cells to drug and genes required for proliferation 
and survival of HCC cells.  
In this study four genes (AKR1B10, HCAP-G, 
RRM2, and TPX2) were found to be expressed 
strongly in HCC, suggeting their role as potential 
therapeutic targets in hepatocellular carcinoma 
(Satow et al., 2010). 
Gastric cancer 
Note 
Morikawa et al., in 2010, explored the prognostic 
value of RRM2 in 112 gastric cancer samples using 
immunohistochemistry (Morikawa et al., 2010). 
They found that RRM2 expression was limited to 
the neck regions of gastric pits, in normal gastric 
mucosa.  
Moreover, they observed RRM2 overexpression in 
72 cases (64.3%), among 112 gastric cancer tissues. 
In vitro analysis and inhibition of RRM2 systhesis 
by small interfering RNA, inhibited the growth of 
three gastric cancer cell lines, MKN-1, MKN-7, and 
SNU-719.  
Furthermore, they demonstarted that 
overexpression of RRM2 was associated with the 
gastric cancer progression and suppression of its 
function could be considered as a potential 




The inhibitory effect of dopamine on RRM1/2 has 
been reported in Parkinson disease. Dopamine 
inhibits RNR through two pathways: (I) dopamine 
acts as an effective radical scavenger and scavenge 
the tyrosyl radical of RRM2, which is important for 
initiating of catalytic process in RRM1 active site 
and (II) chelates the iron center of RRM2 which 
acts as a chelator for iron and other metals. In 
addition nitric oxide induces dopaminergic 
neuronal cells through inhibiting RNR (Woldman et 
al,. 2005; Ebadi and Sharma, 2003). 
To be noted 
Note 
This study was supported by grants from CCA 
Foundation 2012 (Amir Avan), Iranian grant from 
Department of New Sciences and Technology, 
School of Medicine, Mashhad University of 
Medical Sciences, Mashhad, Iran (Amir Avan). 
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